Marshall Wace, LLP Kezar Life Sciences, Inc. Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $21,684 - $50,643	6,928 Added 54.32%	19,682 $61,000
Q4 2022 Feb 14, 2023	SELL	$6.39 - $8.8 $4.13 Million - $5.68 Million	-645,686 Reduced 98.06%	12,754 $89,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $9.99 Million - $13.4 Million	-1,250,075 Reduced 65.5%	658,440 $5.67 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $6.65 Million - $24.9 Million	1,453,020 Added 319.0%	1,908,515 $15.8 Million
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $5.6 Million - $8.35 Million	455,495 New	455,495 $7.57 Million
Q4 2020 Feb 16, 2021	SELL	$4.77 - $6.58 $206,044 - $284,229	-43,196 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.36 - $5.5 $168,531 - $212,597	-38,654 Reduced 47.23%	43,196 $209,000
Q2 2020 Aug 13, 2020	BUY	$3.6 - $7.75 $294,660 - $634,337	81,850 New	81,850 $423,000
Q4 2019 Feb 14, 2020	SELL	$2.5 - $4.26 $81,307 - $138,547	-32,523 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.0 - $7.58 $61,479 - $155,336	-20,493 Reduced 38.65%	32,523 $107,000
Q2 2019 Aug 14, 2019	BUY	$7.09 - $21.9 $94,672 - $292,430	13,353 Added 33.67%	53,016 $409,000
Q1 2019 May 14, 2019	BUY	$16.83 - $23.75 $667,528 - $941,996	39,663 New	39,663 $704,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $430M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.